# Dupixent (dupilumab) and ocular surface disease

> Why the eczema and asthma drug has been linked to conjunctivitis, keratitis, and vision impairment.

**Canonical URL:** https://drugsmonitor.com/guides/dupixent-eye-side-effects
**Last updated:** 2026-06-11

Dupixent (dupilumab) is an injectable biologic approved for atopic dermatitis, asthma, and other inflammatory conditions. Clinical trials and post-market data show a significant rate of ocular adverse events including conjunctivitis, blepharitis, and keratitis.

Some patients have developed vision-threatening conditions such as corneal ulceration and ocular surface disease requiring intervention. The exact mechanism is not fully understood but may involve modulation of the immune response in ocular tissues.

If you developed eye symptoms during Dupixent treatment, see an ophthalmologist promptly and report the adverse event to the FDA MedWatch program. Consult with counsel if your vision has been affected.

---

*Educational guide from DrugsMonitor.com. Not legal advice.*